Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REICHERT, RACHELLE LEIGH | 1 | 30.0% | +33.7% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| KAUFMAN, CLAIRE M | 1 | 63.2% | +51.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043602 | Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer | KAUFMAN, CLAIRE M | 18d overdue |
| 19080640 | SYSTEM FOR MEDICINAL SUPPLY MONITORING AND MANAGEMENT WITH DIGITAL DISPLAY LABELING | REICHERT, RACHELLE LEIGH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043602 | Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer | KAUFMAN, CLAIRE M | 18d overdue |
| 18447808 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | PUTTLITZ, KARL J | 7d |
| 19080640 | SYSTEM FOR MEDICINAL SUPPLY MONITORING AND MANAGEMENT WITH DIGITAL DISPLAY LABELING | REICHERT, RACHELLE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 3686 | 1 |
| 1646 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19080640 | SYSTEM FOR MEDICINAL SUPPLY MONITORING AND MANAGEMENT WITH DIGITAL DISPLAY LABELING | REICHERT, RACHELLE LEIGH | 3686 | §101§103 | Non-Final OA | — | Pending | Mar 14, 2025 |
| 18447808 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | PUTTLITZ, KARL J | 1646 | §103Other | Non-Final OA | 7d | Pending | Aug 10, 2023 |
| 18043602 | Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer | KAUFMAN, CLAIRE M | 1674 | §102§103§112 | Non-Final OA | 18d overdue | Pending | Mar 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial